Overview

Agent-first workspace for failure claims, preprint watch, and biomedical evidence search.

Ask Claidex

Start with any drug, target, trial, failure pattern, or preprint signal.

Compass: Clinical Trial Navigator

Free clinical trial navigator for clinics. Paste a patient profile to get matched open trials, logistics, and failure context.

Open Compass

Failure Claims

Indexed failure dossiers with primary-source backing. Click a row for the full claim card.

	Title		Target		Trial	Phase	Failure
Aug 26, 2026	Emraclidine's M4 bet ended in a 698-patient extension nobody had a reason to finish	Emraclidine (CVL-231, ABBV-1231, PF-06852231)	CHRM4	AbbVie	NCT05443724	Phase 2	Efficacy	MRS 38	Other
Aug 26, 2026	CBX-12 turned a 10-patient signal into a randomized Phase 2 and lost it	CBX-12 (alphalex pHLIP-exatecan peptide-drug conjugate)	TOP1	Cybrexa Therapeutics	NCT06315491	Phase 2	Efficacy	MRS 39	Oncology
Aug 26, 2026	Checkpoint blockade accelerated renal medullary carcinoma	Ipilimumab plus nivolumab	CTLA4	M.D. Anderson Cancer Center	NCT03274258	Phase 2	Efficacy	MRS 47	Oncology
Aug 26, 2026	LEAP-014 added response in metastatic ESCC and no survival	Lenvatinib (added to pembrolizumab plus platinum chemotherapy)	KDR	Merck Sharp & Dohme LLC	NCT04949256	Phase 3	Efficacy	MRS 70	Oncology
Aug 2, 2026	Camrelizumab plus apatinib could not replace chemotherapy in first-line cervical cancer	Camrelizumab (SHR-1210) plus apatinib	PDCD1	Sun Yat-Sen University Cancer Center	NCT04974944	Phase 2	Efficacy	MRS 40	Oncology
Aug 2, 2026	Early hydrocortisone in sepsis stopped for futility, and the timing hypothesis is still untested	Hydrocortisone (early low-dose intravenous)	NR3C1	Siriraj Hospital, Mahidol University	NCT06217939	Unknown	Efficacy	MRS 50	Infectious Disease
Aug 1, 2026	Rivoceranib in adenoid cystic carcinoma: RM-202 closed three years after its data, on an endpoint the disease rarely moves	Rivoceranib	KDR	Elevar Therapeutics	NCT04119453	Phase 2	Sponsor	MRS 60	Oncology
Aug 1, 2026	Eftilagimod alfa in metastatic breast cancer: AIPAC-003 stopped at the lead-in, and the Phase 3 it was meant to feed never opened	Eftilagimod alfa	LAG3	Immutep S.A.S.	NCT05747794	Phase 2/3	Sponsor	MRS 46	Oncology

1–8 of 100

Preprint Watch

Latest bioRxiv preprints flagged against the clinical failure record. Click a row for the full preprint card.

	Title		Disease			DOI
Aug 26, 2026	Oncogene-Mechanics Axis: KRAS G12C Confers Agility Enabling Malignant Mechano-responses to Peristalsis in Colorectal Cancer	KRAS	Colorectal cancer	1 prior	Mild	10.64898/2026.04.28.721453
Aug 26, 2026	Chronic trazodone treatment consolidates sleep, improves memory, and reduces amyloid pathology in a mouse model of Alzheimer's disease	APP	Alzheimer's disease	1 prior	Moderate	10.64898/2026.08.20.746036
Aug 26, 2026	Syndecan-4 exerts canonical heparan sulfate-dependent and noncanonical heparan sulfate-independent functions that regulate Aβ amyloid homeostasis	APP	Alzheimer's disease	1 prior	Moderate	10.64898/2026.08.21.743990
Aug 26, 2026	Lipid anchor engineering controls cell-penetrating arginine-rich peptide presentation for efficient siEGFR liposomal delivery to triple-negative breast cancer cells	EGFR	Triple-negative breast cancer	1 prior	Mild	10.64898/2026.08.20.745705
Aug 26, 2026	IL-12 restores the sequential cytotoxic capacities of anti-GD2 CAR-T and CAR-iNKT cells against glioblastoma	IL12B	Glioblastoma	1 prior	Moderate	10.64898/2026.08.23.746558
Aug 26, 2026	Prefrontal cortex glucocorticoid receptors during fear memory consolidation shift the balance between salience and default-mode networks at retrieval in rats	NR3C1	Post-traumatic stress disorder and fear memory generalisation	2 prior	Moderate	10.64898/2026.08.21.745892
Aug 26, 2026	Humanized APP is the primary determinant of regional brain volume in humanized APOE knock-in mice: a cross-sectional ex vivo MRI study	APP	Alzheimer's disease	1 prior	Moderate	10.64898/2026.05.04.722764
Aug 26, 2026	Membrane PI(4,5)P2 and ErbB2 abundance regulate ErbB receptor signaling through receptor oligomerization and activation	ERBB2	HER2-expressing solid tumours	2 prior	Moderate	10.64898/2026.08.24.746611

1–8 of 70